Neovacs S.A. (EPA:ALNEV)

Market Cap	94.61K
Revenue (ttm)	433.94K
Net Income (ttm)	-32.91M
Shares Out	476.63K
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,828
Average Volume	28,305
Open	0.3900
Previous Close	1.8000
Day's Range	0.3801 - 0.4000
52-Week Range	0.2400 - 8,000.0000
Beta	-45.65
RSI	23.84
Earnings Date	Sep 4, 2025

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.